Ser262
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.8
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser262  -  MDM2 (human)

Site Information
DsEDYsLsEEGQELs   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 454944

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 3 ) , immunoprecipitation ( 1 ) , mass spectrometry (in vitro) ( 2 ) , mutation of modification site ( 1 , 3 ) , phospho-antibody ( 3 ) , phosphopeptide mapping ( 3 ) , western blotting ( 1 , 3 )
Disease tissue studied:
lung cancer ( 1 , 3 ) , non-small cell lung cancer ( 1 , 3 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Kinases, in vitro:
CK1D (human) ( 2 )
Treatments:
ionizing_radiation ( 3 )

Downstream Regulation
Effects of modification on MDM2:
activity, induced ( 3 )

References 

1

Zheng Z, et al. (2012) 5-Aza-2'-deoxycytidine reactivates gene expression via degradation of pRb pocket proteins. FASEB J 26, 449-59
21990374   Curated Info

2

Inuzuka H, et al. (2010) Phosphorylation by casein kinase I promotes the turnover of the Mdm2 oncoprotein via the SCF(beta-TRCP) ubiquitin ligase. Cancer Cell 18, 147-59
20708156   Curated Info

3

Blattner C, Hay T, Meek DW, Lane DP (2002) Hypophosphorylation of Mdm2 augments p53 stability. Mol Cell Biol 22, 6170-82
12167711   Curated Info